Drug Study
Drug Study
Drug Study
SIMVATATIN
Class:
Indication: For the treatment of hypercholesterolemia and for the reduction in the risk of cardiac heart
disease mortality and cardiovascular events. It can also be used in adolescent patients for the treatment of
heterozygous familial hypercholesterolemia.
MOA: Simvastatin is a prodrug in which the 6-membered lactone ring of simvastatin is hydrolyzed in
vivoto generate the beta,delta-dihydroxy acid, an active metabolite structurally similar to HMG-CoA
(hydroxymethylglutaryl CoA). Once hydrolyzed, simvastatin competes with HMG-CoA for HMG-CoA
reductase, a hepatic microsomal enzyme. Interference with the activity of this enzyme reduces the
quantity of mevalonic acid, a precursor of cholesterol.
S/E: Headache.
Difficulty sleeping.
Flushing of the skin.
Muscle aches, tenderness, or weakness (myalgia)
Drowsiness.
Dizziness.
Nausea or vomiting.
Abdominal cramping or pain.